Patient characteristics and long-term outcomes
| Patient* . | Age, y . | Sex . | Histology . | CNS involvement . | Disease status at SCT† . | Previous lines of therapy . | T-cell dose level . | Toxicity‡ . | Progressed . | Status at last follow-up . | Response duration at last follow-up (mo) . | Persistence of CAR T-cells at last follow-up . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 59 | M | Primary CNS DLBCL | Yes | Residual disease | 4 | 5 × 105/m2 | None | Yes | Alive, in remission | 51.5 | Not done |
| 2 | 55 | M | DLBCL | No | Residual disease | 3 | 5 × l08/m2 | None | No | Alive, in remission | 66.5 | Yes |
| 3 | 36 | M | DLBCL | Yes | CR | 2 | 5 × l09/m2 | None | No | Alive, in remission | 42.5 | No |
| 4 | 48 | M | Follicular | No | Residual disease | 3 | 5 × l02/m2 | None | No | Alive, in remission | 60 | Yes |
| 5 | 61 | M | Transformed DLBCL§ | No | CR | 2 | 5 × l08/m2 | None | No | Alive, in remission | 40.5 | No |
| 6 | 47 | M | MCL | No | CR | 2 | 5 × l09/m2 | None | No | Died, in remission | 29.5 | Yes |
| 7 | 58 | M | Transformed DLBCLǁ | No | CR | 3 | 5 × l08/m2 | None | No | Alive, in remission | 64 | Yes |
| Patient* . | Age, y . | Sex . | Histology . | CNS involvement . | Disease status at SCT† . | Previous lines of therapy . | T-cell dose level . | Toxicity‡ . | Progressed . | Status at last follow-up . | Response duration at last follow-up (mo) . | Persistence of CAR T-cells at last follow-up . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 59 | M | Primary CNS DLBCL | Yes | Residual disease | 4 | 5 × 105/m2 | None | Yes | Alive, in remission | 51.5 | Not done |
| 2 | 55 | M | DLBCL | No | Residual disease | 3 | 5 × l08/m2 | None | No | Alive, in remission | 66.5 | Yes |
| 3 | 36 | M | DLBCL | Yes | CR | 2 | 5 × l09/m2 | None | No | Alive, in remission | 42.5 | No |
| 4 | 48 | M | Follicular | No | Residual disease | 3 | 5 × l02/m2 | None | No | Alive, in remission | 60 | Yes |
| 5 | 61 | M | Transformed DLBCL§ | No | CR | 2 | 5 × l08/m2 | None | No | Alive, in remission | 40.5 | No |
| 6 | 47 | M | MCL | No | CR | 2 | 5 × l09/m2 | None | No | Died, in remission | 29.5 | Yes |
| 7 | 58 | M | Transformed DLBCLǁ | No | CR | 3 | 5 × l08/m2 | None | No | Alive, in remission | 64 | Yes |
M, male; MCL, mantle cell lymphoma.
At relapse: Patients 2, 3, and 7 have a low-intermediate, low, and high-intermediate Age-Adjusted International Prognostic Index (IPI), respectively. Patient 4 has intermediate 2 follicular lymphoma IPI. Patient 5 has low-intermediate IPI. Patient 6 has low MCL IPI.
Patient 1 has residual disease according to magnetic resonance imaging of the brain. Patients 2 and 4 had residual disease according to positron emission tomography scan.
Unexpected toxicities not otherwise expected from ASCT.
Transformed from low-grade follicular lymphoma.
Transformed from nodular Hodgkin lymphoma.